Expert panel set to review Boehringer’s Pradaxa

On September 20, an FDA expert panel will review Boehringer Ingelheim's Pradaxa (dabigatran), an experimental blood thinner that the company says is safer, more effective and simpler to use than the generic warfarin. The drug is indicated to prevent stroke in those with irregular heartbeats. It's good news for Boehringer, as some analysts speculated an expert panel wouldn't be scheduled to review Pradaxa until 2011. Bristol-Myers Squibb and partner Pfizer, Merck and Daiichi Sankyo are all...